1. Charting the Biosimilar and Biobetter Development Pipeline
http://www.aarkstore.com/reports/Charting-the-Biosimilar-and-Biobetter-Development-Pipeline-
99086.html
http://www.aarkstore.com/images/3.gif
Related Report Links:
Charting the Biosimilar and Biobetter Development Pipeline
Active Pharmaceutical Ingredients (API) Market in the Americas to 2017 - Shift Towards Generics and
Biosimilars as South and Central America Emerges as a Key Growth Region
Biosimilars in Developed Countries - Launch of Biosimilar mAbs in Europe and New Regulatory Pathways
in the US to Spur Market Growth
Global Biosimilars Market Report: 2012 Edition
Biosimilars in Emerging Economies - Advanced Recombinant Technology Platforms and Low Cost
Manufacturing Put India and China at a Strategic Advantage in Biosimilar Production
Biosimilars: Current Situation & Future Prospects, Worldwide
Global Biosimilar Market 2010-2014
Gauging the Biosimilar Effect: will the market boom or bust?
Biosimilar Drugs in Europe: threat or opportunity to innovation?
Biosimilar/Follow-on Biologics Market Report & Forecast: A Focus on the US (2011-2020)
Biologics Price Competition and Innovation (BPCI) Act - Industry Trends Creating Demand for Biosimilars
Biosimilar development has failed to meet expectations in recent years, but that is set to change.
With a new U.S. biosimilars approval pathway imminent, and the expiration of many top-selling biologics on the horizon, existing
biosimilar developers and newcomers are highly motivated to invest in the biosimilar field and are turning their attention to more
complex biologics, such as monoclonal antibodies. Global sales of biologics are projected to reach $200bn in 2014 (from $138bn in
2010), making it a potentially lucrative market for biosimilar developers.
Originator, generics, and biosimilar companies alike need to be informed about the latest development trends and to know the
likely patent expiration of marketed products and status of products in development. However, market intelligence has been widely
dispersed, making it very difficult for companies to assess potential competition and areas of opportunity, until now.
FirstWord has gathered the very latest intelligence from BIOPHARMA, the Orange Book, literature, industry associations, company
websites, and many other secondary sources to provide a single, authoritative guide to currently marketed and in-development
biosimilar products.
Report Overview
In Charting the Biosimilar and Biobetter Development Pipeline , you’ll find details of currently marketed biosimilar and biobetter
drugs, and all biosimilar and biobetter drugs known to be in clinical development.
Through more than 60 intuitive tables and charts, you will receive unique insights into high-level trends and significant

2. developments, and can easily drill down to details of a specific product or therapeutic area.
Need to know when Drug X will expire? Expiration dates for reference products draw on analysis of products, active agents, and
manufacturing processes to go far beyond the Orange Book.
Need to know who is developing biobetters for interferons? Access a complete list with generic and candidate names, developers,
reference products, and earliest possible EU/US launch dates.
The report’s author has also included concise commentary throughout, providing valuable context and key insights.
For a complete guide to biosimilars at your fingertips, download Charting the Biosimilar and Biobetter Development Pipeline today.
Key Report Features
More than 60 exclusive tables and charts, offering a complete and illuminating view of the biosimilar pipeline
Up-to-the-minute details of ALL biosimilars/biobetters known to be in development in US and EU markets, with their development
status and earliest potential launch dates
Information on international biogenerics that may seek approval as biosimilars/biobetters in US and EU markets
Comprehensive list of reference products, with key sales data and expected patent expiration dates
Detailed analysis of the biosimilar pipeline and market by reference products, therapeutic area, drug class, and compound class
Reports showing the most active companies, regions, and countries
Insights into areas of most intense competition and greatest potential opportunity
Concise commentary highlighting key findings, and providing valuable market intelligence
Definitions of key terms and concepts
Key Benefits
Understand the universe of biosimilar and biobetter development
Get the complete picture of all products in the biosimilar pipeline
Know the latest status on specific biosimilar andbiobetter products of interest to you
Read about the most significant developments in every therapeutic area
Discover the levels of potential biosimilar and biobetter competition by therapy area and drug class
Analyze the size of the threat to your company’s biologic portfolio
Learn which companies are potential future competitors
Key Questions Answered
When is the earliest potential launch for “Biosimilar X”?
What biosimilars are being developed in each therapeutic area, drug class, and compound class?
Which reference products are most targeted by biosimilar and biobetter developers?
Is the reference product sales value the key factor shaping biosimilar development priorities?
Which therapy areas are going to experience the most and fewest biosimilar entries?
Which companies are most active in the biosimilar and biobetter arena?
Which biosimilar companies have been most successful in getting their products onto the market?
How many new biosimilars will be on the market by 2014?
Who Should Read This Report?
Strategic executives at originator, generic, and biosimilar/biobetter development companies, especially in:
Sales and Marketing
Regulatory Affairs
IP and Patent Affairs
Market Research
Research & Development
Business Development
Medical Communications
Table of Contents :
Executive summary
Introduction
Definitions and methodology
Scope and coverage
Glossary
Methodology
Patents
Indexing by indication
Indexing by phase of development
Nomenclature

3. Reference products
Top20 Reference Products
Biosimilars in development
Biosimilars by earliest potential launch date — US & EU
Biosimilars by class and earliest potential launch date in the US (total number)
Biosimilars by class and earliest potential launch date in the EU (total number)
Biosimilar developers countries and regions
Biosimilars in development by drug class
Leading biosimilar companies - number of biosimilar products in portfolio
Biosimilar development pipelines by compound class and therapy area
Biosimilar development pipelines by compound class
Immunomodulators
Interferons
mAb Immunomodulators
Cytotoxic mAbs
Erythropoietin
G-CSF
Insulins
Other Hormones (excluding insulins)
Biosimilar development pipelines by therapy area
Endocrine and metabolic disorders
Haematology
Infectious and Parasitic Disease
Musculoskeletal disorders
Neurology
Neuromuscular diseases
Obstetrics/gynaecology
Oncology
Ophthalmology
Biobetters in development
Biobetter developments by compound class and therapy area
Biobetter development by therapy area and stage
Biobetters by class and earliest potential launch in the US
Biobetters by class and earliest potential launch in the EU
Biobetter developers by compound class
Biobetter development pipeline by compound class
Immunomodulators
Interferons
mAb Immunomodulators
Cytotoxic mAbs
Erythropoietins
Others (Enzymes, Blood Clotting Factors)
Other Hormones (excluding insulins)
Biobetter development pipeline by therapy area
Autoimmune disease
Autoinflammatory disease
Cardiovascular diseases
Dermatology
Endocrine and metabolic disorder
Haematology
Infectious and parasitic disease
Musculoskeletal disorders
Neurology
Obstetrics/gynaecology
Oncology
Respiratory disease
Wound care
Product profiles
Related Keywords : Charting , Biosimilar,Biobetter, Development, Pipeline
For More details about above & other Reports plz contact :
Pranali
Aarkstore.com

4. Contact: Marketing team
Mob.No.918149852585
Email: enquiry@aarkstore.com , discount@aarkstore.com
URL: http://www.aarkstore.com
http://in.linkedin.com/in/aarkstore
http://www.facebook.com/aarkstore